Hey, everyone. It's Adam from Elite Trade Club. Here’s what moved the market today.
In partnership with
The key to a $1.3T opportunity
A new trend in real estate is making the most expensive properties obtainable. It’s called co-ownership, and it’s revolutionizing the $1.3T vacation home market.
The company leading the trend? Pacaso. Created by the founder of Zillow, Pacaso turns underutilized luxury properties into fully-managed assets and makes them accessible to the broadest possible market.
The result? More than $1b in transactions, 2,000+ happy homeowners, and over $110m in gross profits for Pacaso.
With rapid international growth and 41% gross profit growth last year, Pacaso is ready for what’s next. They even recently reserved the Nasdaq ticker PCSO.
But the real opportunity is now, before public markets. Until 5/29, you can join leading investors like SoftBank and Maveron for just $2.80/share.
This is a paid advertisement for Pacaso’s Regulation A offering. Please read the offering circular at invest.pacaso.com. Reserving a ticker symbol is not a guarantee that the company will go public. Listing on the NASDAQ is subject to approvals. Under Regulation A+, a company has the ability to change its share price by up to 20%, without requalifying the offering with the SEC.
Markets
Wall Street was mixed on Friday, weighed down by U.S.-China trade worries. Nevertheless, the benchmark indices posted the biggest monthly gains since late 2023.
DJIA [+0.13%]
S&P 500 [-0.01%]
Nasdaq [-0.32%]
Russell 2k [-0.18%]
Market-Moving News
Oil & Gas
EOG Spends $5.6 Billion and Expands Deep into Utica, Gains Over 1 Billion Barrels in New Reserves
EOG Resources (NYSE: EOG) will acquire Encino Acquisition Partners in a $5.6 billion deal, including debt, to scale its operations in the Utica shale basin. The move adds 675,000 net core acres and over 1 billion barrels of undeveloped resources to EOG’s portfolio, solidifying its presence in one of the most prolific gas-producing regions in the U.S.
The purchase strengthens EOG’s footprint in Ohio, giving it greater access to premium markets through Encino’s existing pipeline capacity. Encino has already secured transport for more than 800 million cubic feet of natural gas per day, enabling EOG to reach customers across the Gulf Coast, Southeast, Northeast, and Midcontinent regions.
This deal suggests that EOG is playing the long game in natural gas, betting on sustained demand and leveraging its scale to lower its cost structure. The added infrastructure and reserves could position the company for stronger returns in future cycles, especially as demand for U.S. gas rises globally.
By gaining firm transport access to premium regions, EOG strengthens its ability to secure better margins, regardless of local price fluctuations. The size of the resource also gives it flexibility in timing production, allowing it to respond to global pricing dynamics without rushing development.
EOG plans to fund the transaction with $3.5 billion in debt and $2.1 billion in cash. The deal is expected to close in the second half of the year. Alongside the announcement, EOG increased its regular dividend by 5%, reinforcing confidence in its balance sheet strength and earnings outlook.
AI Trade Shift (Sponsored)
As U.S.-China trade tensions rise, chip exports are being restricted—and big names like Nvidia could face major revenue hits.
But this disruption is creating space for U.S.-based AI companies with strong domestic operations and rapid revenue growth.
A new report reveals 9 under-the-radar AI stocks poised to benefit from this shift.
Download the full list today—free for a limited time.
Energy
U.S. Axes Exxon’s Hydrogen $332M Grant, Undermining Low-Carbon Ambitions
Exxon Mobil (NYSE: XOM) has lost a major clean energy grant as the U.S. Department of Energy cancels more than $3.7 billion in awards, including nearly $332 million for a hydrogen project at its Baytown, Texas, refinery.
This move marks a shift in federal energy priorities under the Trump administration, which is reevaluating support for clean tech efforts initiated during the Biden presidency.
The Baytown project aimed to cut carbon emissions by replacing natural gas with hydrogen in the production of ethylene, a key component used in plastics and textiles. The loss of funding could delay or derail Exxon’s plans to scale up low-emissions technologies at one of its largest U.S. sites.
For Exxon, the grant cancellation adds pressure to balance its core fossil fuel business with ongoing efforts to invest in carbon capture and hydrogen. The company has highlighted its Baytown complex as a proving ground for future-ready technologies.
Investors watching Exxon’s energy transition strategy may now question how the company will fund or prioritize such initiatives without federal support. The outcome underscores how quickly policy shifts can reshape the economics of decarbonization for even the largest energy players.
The timing of this reversal matters. With global pressure mounting on oil majors to clean up their operations, Exxon now faces tougher questions about strategy and execution.
High-Rated Buys (Sponsored)
A new investor report reveals 7 stocks with breakout potential in the next 30 days.
These picks come from a proven ranking system that has more than doubled the S&P 500’s return—posting +24.2% average annual gains.
Only the top 5% of stocks even qualify, and these 7 are rated the highest right now.
The opportunity window is closing fast.
Download the full list—free.
Access the “7 Best Stocks for the Next 30 Days” now.
(By submitting your email, you’ll also get a free Profit from the Pros membership, which highlights exclusive market updates and daily Strong Buy stocks. You can unsubscribe at any time. Privacy Policy)
Enterprise
Synopsys Pulls Out of China After U.S. Export Crackdown
Synopsys (NASDAQ: SNPS) has suspended all product sales, order fulfillment, and customer support in China following a directive from the U.S. Commerce Department. The company responded after receiving a notice tied to expanded export restrictions on sensitive chip technologies.
This abrupt freeze applies to all Chinese customers, including employees of multinational firms operating in China. Synopsys has also disabled access to its support portal, SolvNetPlus, in the region while awaiting further guidance.
What’s at stake isn’t just a temporary sales freeze but Synopsys’s ability to operate freely in one of its largest international markets. The company’s core role in global chip design makes it a critical player, but also a vulnerable one when geopolitical shifts escalate. For investors, this escalation adds fresh uncertainty to Synopsys’s international revenue stream and raises new questions about long-term growth in Asia.
Alongside Cadence and Siemens EDA, Synopsys provides essential tools for designing semiconductors used in everything from smartphones to cars.
Losing such a large customer base will not go unnoticed by investors. As the U.S.-China tech rivalry intensifies, the risk calculus for American firms with significant exposure to China has shifted, and Synopsys is now at the forefront.
Top Winners and Losers
Red Robin Gourmet Burgers Inc [RRGB] $5.08 (+62.31%)
Red Robin Gourmet Burgers stock soared after the company posted strong Q1 earnings that beat expectations, driven by price hikes and lower food and labor costs.
Biolinerx Ltd [BLRX] $5.25 (+35.31%)
BioLineRx shares rose after the company announced encouraging early data from its pancreatic cancer trial, showing durable responses and complete remissions in some patients.
Verb Technology Company [VERB] $8.09 (+24.08%)
Verb Technology rallied after Ascendiant Capital reiterated a Buy rating and raised its price target, prompting investor confidence in the stock’s potential.
Summit Therapeu [SMMT] $18.21 (-30.50%)
Summit plunged after its latest Phase 3 lung cancer trial failed to show a statistically significant survival benefit, raising concerns about FDA approval prospects.
Gap Inc [GAP] $22.31 (-20.18%)
Gap fell despite strong Q1 results as investors focused on the company’s warning that new U.S. tariffs could cost it up to $300 million this year.
Regeneron Pharmaceuticals [REGN] $489.52 (-19.14%)
Regeneron dropped on disappointing results of a key lung drug trial, which missed the primary endpoint.
Q2 Market Movers (Sponsored)
Summer market momentum is here—and these 7 tickers are at the center of it.
This free investor guide features top-ranked stocks selected for their growth potential, market trends, and expert analysis.
It’s a must-read for anyone looking to position their portfolio for a strong second half.
The list is available for FREE, but only for a limited time.
Grab the “Top 7 Stocks for Q2 2025” Now
That's it for today! Please, write us back, and let us know what you think of the Closing Bell Roundup. We're always eager to hear feedback!
Thanks for reading. I'll see you at the next open!
Best Regards,
— Adam G.
Elite Trade Club
Click here to get our daily newsletter straight to your cell for free.
P.S. Just like this newsletter, it's 100% free*, and you can stop at any time by replying STOP.
